Journal article
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Abstract
BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase inhibitor sofosbuvir combined with the NS5A inhibitor velpatasvir. We assessed the efficacy of 8 weeks of treatment with sofosbuvir and velpatasvir plus the pangenotypic NS3/4A protease inhibitor voxilaprevir (sofosbuvir-velpatasvir-voxilaprevir).
METHODS: In …
Authors
Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B
Journal
Gastroenterology, Vol. 153, No. 1, pp. 113–122
Publisher
Elsevier
Publication Date
July 2017
DOI
10.1053/j.gastro.2017.03.047
ISSN
0016-5085
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAged, 80 and overAminoisobutyric AcidsAntiviral AgentsCarbamatesCyclopropanesDrug Therapy, CombinationFemaleHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsHumansLactams, MacrocyclicLeucineMacrocyclic CompoundsMaleMiddle AgedProlineQuinoxalinesSofosbuvirSulfonamidesSustained Virologic ResponseYoung Adult